Jacobs Levy Equity Management
LCTX icon

Jacobs Levy Equity Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,033,763
Closed -$519K – 1147
2024
Q4 		$519K Buy
+1,033,763
New +$759K ﹤0.01% 810
2023
Q1 		– Sell
-202,202
Closed -$237K – 1019
2022
Q4 		$237K Sell
202,202
-55,259
-21% -$69.6K ﹤0.01% 889
2022
Q3 		$291K Buy
+257,461
New +$378K ﹤0.01% 891
2018
Q3 		– Sell
-118,687
Closed -$214K – 1035
2018
Q2 		$214K Buy
118,687
+38,876
+49% +$78.3K ﹤0.01% 947
2018
Q1 		$188K Sell
79,811
-68,819
-46% -$161K ﹤0.01% 937
2017
Q4 		$280K Sell
148,630
-13,393
-8% -$29.2K ﹤0.01% 853
2017
Q3 		$403K Buy
162,023
+30,568
+23% +$75.8K 0.01% 737
2017
Q2 		$362K Buy
+131,455
New +$367K 0.01% 740

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jacobs Levy Equity Management's LCTX Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2025, closing a stake of 1,033,763 shares — an estimated $519K sold.

Jacobs Levy Equity Management first reported a position in LCTX in Q2 2017 and held it in 8 quarters. The position peaked at $519K in Q4 2024. 127 funds tracked by Wall St. Rank hold LCTX as of Q1 2025.

  • Jacobs Levy Equity Management reported no remaining Lineage Cell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 1,033,763 Lineage Cell Therapeutics shares in Q1 2025, an estimated $519K.
  • Jacobs Levy Equity Management first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 8 quarters.
  • Jacobs Levy Equity Management's Lineage Cell Therapeutics position peaked at $519K in Q4 2024.
  • 127 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.